12 completed, 5 recruiting, 3 terminated, 1 unknown. 8 Phase 3, 4 Phase 2, 2 Not applicable, 2 Phase 4, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 6, Recruiting 2 |
| Phase 2 | 4 | Completed 2, Terminated 1, Unknown 1 |
| Not applicable | 2 | Completed 1, Withdrawn 1 |
| Phase 4 | 2 | Recruiting 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow von Willebrand Factor: new trials by email Literature Review of von Willebrand Factor trials Research Report on von Willebrand Factor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease Emicizumab, von Willebrand Factor (VWF) Concentrates, Factor VIII (FVIII) Concentrates - Von Willebrand Disease, Type 3 | Phase 3 | Recruiting | Hoffmann-La Roche | 75 | 2025-06-27 | 2026-10-09 |
| A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients With VWD Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII, Placebo - Von Willebrand Diseases | Phase 3 | Recruiting | Unity Health Toronto | 20 | 2024-10-21 | 2026-10-14 |
| Enhancement of the Haemostatic Effect of Platelets in the Presence of High Normal Concentrations of Von Willebrand Factor Wilate, Placebo - Bleeding | Phase 4 | Recruiting | University Hospital, Basel, Switzerland | 120 | 2022-04-01 | 2026-06-11 |
| Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age Wilate - Von Willebrand Disease | Phase 3 | Completed | Octapharma | 12 | 2021-09-22 | 2026-02-20 |
| Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD Wilate - Von Willebrand Diseases | Phase 3 | Completed | Octapharma | 43 | 2020-06-18 | 2023-10-25 |
| Treatment of Hemophilia A Patients With FVIII Inhibitors Nuwiq, Octanate, Wilate - Hemophilia A | Recruiting | Emory University | 120 | 2020-03-17 | 2026-09-23 | |
| Von Willebrand Factor in Pregnancy (VIP) Study Use of a postpartum diary and additional blood draws, VWF replacement therapy with Wilate, Tranexamic acid - Von Willebrand Diseases | Recruiting | University of Washington | 110 | 2019-10-12 | 2025-12-18 | |
| Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment Von Willebrand Factor-Containing Product - Von Willebrand Diseases | Completed | Octapharma | 56 | 2019-06-25 | 2023-12-07 | |
| Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq Wilate or Nuwiq - Hemophilia A | Terminated | Octapharma | 14 | 2018-06-28 | 2024-08-09 | |
| Von Willebrand Factor Concentrate During ECMO Support Von Willebrand Factor, Saline Solution - Acquired Von Willebrand Disease | Phase 2 | Unknown | Tirol Kiniken GmbH | 68 | 2018-04-16 | 2020-03-12 |
| Alphanate in Immune Tolerance Induction Therapy Alphanate - Hemophilia A, Congenital | Phase 2 | Terminated | Grifols Therapeutics LLC | 2 | 2018-01-03 | 2021-11-23 |
| Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A Wilate - Severe Hemophilia A | Phase 3 | Completed | Octapharma | 11 | 2017-11-22 | 2021-01-19 |
| rVWF IN PROPHYLAXIS von Willebrand factor (Recombinant), Antihemophilic Factor (Recombinant) - Von Willebrand Disease | Phase 3 | Completed | Takeda | 29 | 2017-11-16 | 2021-08-06 |
| Molecular and Clinical Profile of Von Willebrand Disease in Spain VWF gene analysis - Von Willebrand Disease | Completed | Spanish Society of Thrombosis and Haemostasis | 790 | 2017-10-03 | 2025-03-12 | |
| INdividualized ITI Based on Fviii(ATE) Protection by VWF Wilate - Hemophilia A With Inhibitor, Hemophilia A | Phase 4 | Terminated | University of California, Davis | 1 | 2017-06-01 | 2020-05-29 |
| Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A Wilate - Severe Hemophilia A | Phase 3 | Completed | Octapharma | 57 | 2016-12-01 | 2021-01-19 |
| Type 3 Von Willebrand International Registries Inhibitor Prospective Study Von Willebrand Factor - Type 3 Von Willebrand's Disease | Completed | Fondazione Angelo Bianchi Bonomi | 265 | 2012-11-05 | 2024-12-27 | |
| Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced) VWF/FVIII concentrates - Severe Hemophilia A | Not applicable | Completed | City of Hope Medical Center | 3 | 2009-11-03 | 2021-08-23 |
| Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive FVIII Concentrates, FVIII/VWF concentrates - Severe Hemophilia A | Not applicable | Withdrawn | City of Hope Medical Center | 2009-09-25 | 2020-12-17 | |
| Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease Biostate® - Von Willebrand Disease | Phase 2 / Phase 3 | Completed | CSL Behring | 22 | 2009-06-01 | 2017-10-03 |
Showing 20 of 22. Sign in to see all of them.
Hemophilia A (10) · von Willebrand Diseases (10) · Hematologic Diseases (2) · Hemorrhage (2) · von Willebrand Disease, Type 3 (2) · Disease (1) · Postpartum Hemorrhage (1) · Rare Diseases (1)
Octapharma (6) · CSL Behring (2) · City of Hope Medical Center (2) · Emory University (1) · Fondazione Angelo Bianchi Bonomi (1) · Grifols Therapeutics LLC (1) · Hoffmann-La Roche (1) · National Center for Research Resources (NCRR) (1) · Spanish Society of Thrombosis and Haemostasis (1) · Takeda (1) · Tirol Kiniken GmbH (1) · Unity Health Toronto (1) · University Hospital, Basel, Switzerland (1) · University of California, Davis (1) · University of Washington (1)
United States (10) · Russia (9) · Bulgaria (5) · Canada (5) · Germany (5) · Spain (5) · Ukraine (5) · Hungary (4) · Italy (4) · Poland (4) · France (3) · Netherlands (3) · Belarus (2) · Croatia (2) · Lebanon (2)
Cristina Solomon, MD (3) · Augusto B. Federici, MD (1) · Barbara A Konkle, M.D. (1) · Cristina Solomon (1) · Gilbert C. White (1) · Jill M Johnsen, M.D. (1) · Martin Siegemund, Prof. Dr. MD (1) · Nadia P Ewing, MD (1) · Nadia P. Ewing, MD (1) · Peter A Kouides, M.D. (1) · Robert Sidonio, MD, MSc (1) · Sri Adapa (1)
PMID 38237075, PMID 16247740, PMID 16359502, PMID 16634745, PMID 16634746, PMID 16889557, PMID 16985174, PMID 17488667, PMID 18315556, PMID 18344424, PMID 19277422, PMID 19566550, PMID 19786936, PMID 20801902, PMID 21199188, PMID 21251206, PMID 22102193, PMID 22197721, PMID 22507569, PMID 23349392, PMID 23633542, PMID 25077350, PMID 2584182, PMID 26245874, PMID 28971901, PMID 29924855, PMID 30361419, PMID 31041796, PMID 32135566, PMID 34589194, PMID 35439298, PMID 36670471, PMID 36861346, PMID 38314243, PMID 41278463, PMID 41614378
2008 (3), 2015 (1), 2016 (1)